ENTA - חוב כולל להון Enanta Pharmaceuticals, Inc

Enanta Pharmaceuticals (ENTA) bases its business on licensing fees from the commercialization of antiviral agents and the development of its own drugs for liver and respiratory diseases. This chart from GURU.Markets illustrates a total debt-to-equity ratio of 1.90. A steady stream of royalties from global corporations for the use of patented molecular formulas ensures financial stability. At the same time, the brand's high scientific reputation in virology is coupled with volatility in investment demand.

The debt_total_eq_co ratio measures the degree of financial leverage by comparing total liabilities to equity. This chart of the total liabilities-to-equity ratio allows for an assessment of the company's dependence on borrowed funds. For Enanta Pharmaceuticals (ENTA), low leverage is supported by stable licensing payments from pharma behemoths for the use of patented formulas. A decrease in this metric confirms the growth of business autonomy, which guarantees the high resilience of the asset.